Prenetics Plunges 38% to 52-Week Low as 2H EBITDA Loss Guidance Widens to $30M-$35M
PRE is trading near its 52-week low of $9.134 (11% above the low) on elevated volume (3.5× avg).
Summary
Prenetics cut its second-half outlook hard: adjusted EBITDA is now expected to be a loss of $30 million to $35 million, versus prior guidance of an $8 million to $12 million loss. Management says the change is deliberate — it is spending more to acquire customers while returns on them are strong — but the market read it as a cost problem, not an investment. Q3 revenue of $64.1 million beat the $63.2 million FactSet consensus and rose more than threefold, yet the loss widened to $25.4 million, or $1.45 a share, from $8.7 million, or 53 cents, a year earlier; that included a $7.2 million noncash fair-value loss on warrant liabilities. Shares fell 38% to $10.08, a new 52-week low, and are down 36% year to date. The gap between triple-digit revenue growth and a ballooning loss is the whole story — the IM8 brand is scaling fast, but the spending to get there is now far above what the company told investors two months ago.
At the time of this announcement, PRE was trading at $10.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $173.3M. The 52-week trading range was $9.13 to $27.24. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.